Accessibility Menu
Ucb logo

Ucb(OTC) UCBJF

Market Cap$48.54BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+528%
5 Year+155%
1 Year+15%
1 Month-8%
$254.59
-3.23%
-8.50Today
Ucb last closing stock price
MetricPriceDate
Last closeUSD 254.592026-08-14
Ucb stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.48%USD 269.342026-08-07
1 month-7.54%USD 275.342026-07-15
3 month-11.94%USD 289.122026-05-15
Year to date-12.74%USD 291.772025-12-31
1 year+15.24%USD 220.922025-08-14
3 year+191.24%USD 87.422023-08-14
5 year+155.3%USD 99.722021-07-19
Since inception+527.69%USD 40.562004-04-20

Ucb Financials at a Glance

Market Cap

$48.54BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€15.36B

Net Income (TTM)

€3.52B

EPS (TTM)

$13.19

P/E Ratio

18.94

Dividend

$1.70

Beta (Volatility)

-0.02 (Low)

Price

$254.59

Volume

106

Open

$254.59

Previous Close

$254.59

Daily Range

$254.59 - $254.59

52-Week Range

$219.50 - $345.39

Estimated Earnings Date

Feb 25, 2027

UCBJF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ucb

UCB S.A. is a leading biopharmaceutical company focused on developing innovative therapies for neurological and immunological disorders. With a diverse portfolio of products and a strong commitment to research, UCB aims to improve the quality of life for patients worldwide.

Products and Services
  • Cimzia for inflammatory TNF-mediated diseases
  • Vimpat, Keppra, and Briviact for epilepsy management
  • Evenity for osteoporosis treatment in postmenopausal women
Growth Outlook
  • Recent quarterly revenue reached €4.25 billion, indicating strong market demand
  • TTM revenue of €14.5 billion reflects consistent growth trajectory
  • Strategic collaborations with major players enhance research capabilities
Financial Highlights
  • Net income for Q4 2025 was €1.08 billion, showcasing profitability
  • Operating income margin improved to 30.3% in Q4 2025
  • Dividend yield stands at 0.41%, reflecting shareholder returns
UCB S.A. has established itself as a significant player in the biopharmaceutical industry, with a focus on addressing unmet medical needs. The company's diverse product offerings, including treatments for chronic conditions, position it well for future growth. Recent financial performance highlights a robust revenue stream and profitability, which may attract potential investors. The strategic partnerships with industry leaders further bolster UCB's research and development efforts, paving the way for innovative therapies. With a solid foundation and a commitment to improving patient outcomes, UCB S.A. presents a compelling opportunity in the healthcare sector.
AI Generated • Jul 27, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10,117

CEO

Jean-Christophe Tellier, MD

Website

www.ucb.com

Headquarters

Brussels, BU 1070, BE

UCBJF Financials

Key Financial Metrics (TTM)

Gross Margin

76.23%

Operating Margin

31.23%

Net Income Margin

25.74%

Return on Equity

19.48%

Return on Capital

8.89%

Return on Assets

10.63%

Earnings Yield

5.28%

Dividend Yield

0.67%

Payout Ratio

12.58%

Stock Overview

Market Cap

$48.54BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

190.66M

Volume

106

Avg. Volume

718.508

Financials (TTM)

Gross Profit

€11.39B

Operating Income

€4.38B

EBITDA

€5.63B

Operating Cash Flow

€3.42B

Capital Expenditure

-€724.58M

Free Cash Flow

€2.70B

Cash & ST Invst.

€795.81M

Total Debt

€3.58B

Ucb Performance Analysis

Ucb annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 5,798,225,305-15.1%
20232023-12-31EUR 5,678,019,147-2.1%
20242024-12-31EUR 6,654,561,53317.2%
20252025-12-31EUR 8,736,321,91631.3%
Ucb sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3120.4%
Q22025-06-303.7%
Q42025-12-3122.0%
Q22026-06-300.3%
Ucb annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 2.25-65.0%
20232023-12-31EUR 1.90-15.7%
20242024-12-31EUR 5.92211.7%
20252025-12-31EUR 9.0652.9%
Ucb sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31312.1%
Q22025-06-30-44.7%
Q42025-12-31133.2%
Q22026-06-300.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€4.26B

+52.8%

Gross Profit

€3.18B

+64.0%

Gross Margin

74.64%

N/A

Market Cap

$48.54BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.80M

N/A

Employees

10,117

N/A

Net Income

€1.11B

+433.3%

EBITDA

€1.73B

+169.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€795.81M

+85.9%

Total Debt

€3.58B

+17.9%

Accounts Receivable

€2.58B

+88.5%

Inventory

€1.74B

+52.9%

Long Term Debt

€3.37B

+12.8%

Short Term Debt

€216.68M

+301.3%

Return on Assets

10.63%

N/A

Return on Invested Capital

16.54%

N/A

Free Cash Flow

€82.88M

-68.2%

Operating Cash Flow

€320.52M

-15.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LZAGFLonza Group AG
$693.20-1.74%
LZAGYLonza Group AG
$69.10-1.85%
CMXHFCSL Limited
$98.03+0.00%
HLNCFHaleon plc
$4.98+2.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About UCBJF

What is the current price of Ucb?

Ucb is trading at $254.59 per share.

What is the 52-week range for Ucb?

Over the past 52 weeks, Ucb has traded between $219.50 and $345.39.

How much debt does Ucb have?

As of the most recent reporting period, Ucb reported total debt of €2.64B.

How much cash does Ucb have on hand?

Ucb reported €2.64B in cash and cash equivalents in its most recent financial results.

What is Ucb’s dividend yield?

Ucb currently has a dividend yield of 0.67%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services